

Supplemental Table 4: Effectiveness table of the different treatment strategies in the CareRA trial including data from all participants as observed up until and at the week 52 visit

		Total Population	High-Risk			Low-risk	
			COBRA Classic	COBRA Slim (High-Risk)	COBRA Avant-Garde	MTX-TSU	COBRA Slim (Low-Risk)
Total patients included in trial		N=379	N=98	N=98	N=93	N=47	N=43
Patients reaching W52 evaluation		N=346 (91.3%)	N=90 (91.8%)	N=89 (90.8%)	N=85 (91.4%)	N=44 (93.6%)	N=38 (88.4%)
Therapy at W52:	Biological therapy	26 (7.5%)	10 (11.1%)	2 (2.2%)	6 (7.1%)	4 (9.1%)	4 (10.5%)
	MTX+SSZ+GC	6 (1.7%)	5 (5.6%)	1 (1.1%)			
	MTX+LEF+GC	2 (0.6%)		1 (1.1%)	1 (1.2%)		
	MTX+LEF+HCQ	1 (0.3%)		1 (1.1%)			
	MTX+SSZ	9 (2.6%)	9 (10.0%)				
	MTX+LEF	28 (8.1%)		10 (11.2%)	8 (9.4%)	6 (13.6%)	4 (10.5%)
	MTX+GC	9 (2.6%)	2 (2.2%)	2 (2.2%)	2 (2.4%)	1 (2.3%)	2 (5.3%)
	LEF+GC	1 (0.3%)			1 (1.2%)		
	MTX only	236 (68.2%)	58 (64.4%)	71 (79.8%)	43 (50.6%)	33 (75.0%)	27 (71.1%)
	LEF only	26 (7.5%)	1 (1.1%)	1 (1.1%)	24 (28.2%)		
SSZ only	1 (0.3%)	1 (1.1%)					
NSAIDs	1 (0.3)					1 (2.6%)	
Patients in remission at W52		227 (65.6%)	61 (67.8%)	54 (60.7%)	56 (65.9%)	27 (61.4%)	29 (76.3%)
Patients in low disease activity at W52		278 (80.3%)	70 (77.8%)	69 (77.5%)	69 (81.1%)	37 (84.1%)	33 (86.8%)
Patients missing for evaluation at W52		N=33 (8.7%)	N=8 (7.1%)	N=9 (9.2%)	N=8 (8.6%)	N=3 (6.4%)	N=5 (11.6%)

N= number of patients, GC= glucocorticoid, MTX= methotrexate, SSZ= sulphasalazine, LEF= leflunomide, NSAIDs= non-steroidal anti-inflammatory drugs, HCQ= hydroxychlorquine, W52= week 52. Remission was defined as a DAS28(CRP) <2.6. Low Disease Activity was defined as DAS(CRP) ≤3.2; Data are presented as mean ± standard deviation or percentages.